Ausun Pharm(SH:603229)2020-04-29 16:00Financial Performance - Operating revenue for the period was CNY 79,470,646.17, representing a year-on-year increase of 36.16%[12] - Net profit attributable to shareholders was CNY 20,979,644.34, an increase of 169.59% compared to the same period last year[12] - Basic earnings per share were CNY 0.13, reflecting a 160.00% increase from CNY 0.05 in the previous year[12] - The net profit after deducting non-recurring gains and losses was CNY 19,009,382.23, up 255.38% year-on-year[12] - The company's operating revenue for Q1 2020 was CNY 79,470,646.17, representing a 36.16% increase compared to CNY 58,365,261.76 in Q1 2019[27] - Net profit for Q1 2020 reached CNY 20,979,644.34, a significant increase of 169.59% from CNY 7,781,920.30 in the same period last year[27] - The company reported a significant increase in contract liabilities to CNY 5,369,930.62, reflecting an increase in advance payments received[27] - The company reported a total comprehensive income of CNY 18,478,540.07 for Q1 2020, compared to CNY 7,692,935.84 in Q1 2019, indicating a growth of approximately 140.5%[55] Assets and Liabilities - Total assets at the end of the reporting period were CNY 854,019,256.80, a decrease of 3.63% compared to the end of the previous year[12] - Total current assets as of March 31, 2020, were CNY 548,358,047.19, a decrease from CNY 601,626,765.83 at the end of 2019[34] - Non-current assets increased from 284,518,015.17 to 305,661,209.61, an increase of about 7.5%[37] - Current liabilities decreased from 232,148,380.32 to 179,213,420.89, a reduction of approximately 22.7%[37] - Total liabilities decreased from 240,959,423.97 to 187,809,107.88, a decline of around 22.1%[39] - Total equity increased from 645,185,357.03 to 666,210,148.92, an increase of about 3.3%[39] Cash Flow - Net cash flow from operating activities was CNY 16,785,431.35, down 30.90% year-on-year[12] - The company's cash flow from operating activities decreased by 30.90% to CNY 16,785,431.35, down from CNY 24,290,993.20 in the previous year[29] - Cash flow from operating activities in Q1 2020 was CNY 16,785,431.35, down from CNY 24,290,993.20 in Q1 2019, indicating a decrease of approximately 30.8%[59] - Total cash inflow from operating activities was CNY 125,598,572.88, compared to CNY 91,734,169.46 in Q1 2019, reflecting an increase of about 37%[59] - The company reported cash outflow from operating activities totaling CNY 108,813,141.53, which is an increase from CNY 67,443,176.26 in the previous year, representing a rise of approximately 61.4%[59] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,939[16] - The largest shareholder, Zheng Zhiguo, held 59.99% of the shares, totaling 95,976,000 shares[16] Investment and Expenses - Research and development expenses surged by 87.11% to CNY 14,791,850.71, up from CNY 7,905,487.88 in Q1 2019, indicating increased investment in innovation[27] - The company's investment income dropped by 71.80% to CNY 302,856.60, down from CNY 1,074,138.36, due to reduced financial product investments[27] - The financial expenses turned positive with a gain of CNY 5,805,133.37, compared to a loss of CNY 4,930,599.57 in Q1 2019, attributed to favorable exchange rate movements[27] Changes in Financial Position - The company executed new revenue and leasing standards starting January 1, 2020, adjusting previously classified "prepayments" to "contract liabilities," which may impact future revenue recognition[70] - The company has implemented new revenue recognition standards, adjusting previously classified "prepayments" to "contract liabilities"[77]